Click here to print this page

Planning Retirement Online

 

Breakthrough drug for Huntington’s may have implication for Alzheimer’s and other diseases

January 2018

woman comforting man

The development of a new drug that stops Huntington’s disease is now being talked about as one of the biggest medical breakthroughs in half a century.

This is not just for its amazing potential for sufferers of Huntington’s disease but because there is also potential for it to be developed further into personalised treatments for a range of patients with severe genetic diseases.

Huntington’s is an incurable degenerative disease caused by a defect in a single gene that is passed down through families. The first symptoms don’t usually appear until middle age but there is a gradual onset of uncontrolled jerky movements, dementia and ultimately paralysis. About 10,000 people in the UK have the condition and around 25,000 are at risk. Patients usually die within 20 years after the onset of symptoms.

The drug, called Ionis-HTTRx, was developed by the California biotech company Ionis Pharmaceuticals and is based on its ability to intercept and destroy a messenger molecule that spreads the instructions from the faulty Huntington gene. The drug intercepts this messenger molecule and destroys it before it can instruct a toxic protein to be made, effectively silencing the effects of the mutant gene.

Following development of the drug, it was then put into a limited trial co-ordinated by University College London’s Huntington’s Disease Centre. 46 men and women in UK, Germany and Canada were involved in the trials, all suffering from early stage Huntington’s disease. They were each given four spinal injections one month apart and the drug does was increased at each session. Around a quarter of the participants had a placebo instead.

After being given the drug, the concentration of the harmful protein in the spinal cord fluid had dropped significantly, and in precise proportion to the amount of the drug given. This was so closely matched that the researchers were confident the drug was having a powerful effect. There appears to be no major side effects from the drug.

One of the lead researchers in the trials was Professor Sarah Tabrizi, head of University College London’s Huntington’s Disease Centre. She said the results of the drug were probably the most significant moment in the history of Huntington’s since the faulty gene was isolated.

The Swiss pharmaceutical giant Roche has paid a $45m licence fee to take the drug forward now to clinical use and there is now excitement in other areas of the scientific world looking at the potential to adapt the drug to target other incurable brain disorders such as Alzheimer’s and Parkinson’s.



Back to LaterLife Interest Index


Bookmark This Share on Facebook Receive more like this

 

Latest Articles:

Health food of the month: Sugar

Pile of brown and white sugar cubes

It was good news indeed when a report came out from a leading American doctor that sugar is good for us...well at least for our brain.

more

Top tips to achieve a back-friendly car

Back problems can be triggered by poor posture and drivers are particularly at risk. By adjusting and setting up your car seat properly, your posture can be improved and the risk of back pain minimised.

more

Food allergies need to be taken seriously

Range of food on a platter

It is estimated that over 2 million people in the UK have been officially diagnosed with a food allergy and there may well be many more taking their own precautions against problems they have identified with eating certain foods.

more

Keeping track of your health

Team of surgeons operating

Today there is a range of excellent online tools to assist you choose the best treatment.

more

Back to LaterLife Health Section

Visit our Pre-retirement Courses section here on laterlife or our dedicated Retirement Courses site

Bookmark


Advertise on laterlife.com



LaterLife Travel Insurance in Association with Avanti